REG - Destiny Pharma PLC - Notice of Interim Results

Destiny PharmaAnnouncement

22/08/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220822:nRSV6609Wa&default-theme=true

RNS Number : 6609W  Destiny Pharma PLC  22 August 2022

Destiny Pharma plc

("Destiny Pharma" or the "Company")

 

Notice of Interim Results and Investor Presentation

 

Brighton, United Kingdom - 22 August 2022 - Destiny Pharma plc (AIM:
DEST), a clinical stage biotechnology company focused on the development of
novel products to prevent life-threatening infections, will announce its
interim results for the period ended 30(th) June 2022, on Thursday 8(th)
September 2022.

 

Neil Clark, Chief Executive Officer and Shaun Claydon, Chief Financial
Officer, will provide a live presentation on the same day, at 10:00 am BST,
followed by a Q&A session accessible via the Investor Meet Company
platform. The webcast of the presentation will be available on the Company's
investor relations website at www.destinypharma.com
(https://www.destinypharma.com/) .

 

The presentation is open to analysts and all existing and potential new
shareholders. Questions can be submitted pre-event via the Investor Meet
Company Dashboard up until 09:00 am BST the day before the meeting, or at any
time during the live presentation.

 

Investors can sign up to Investor Meet Company for free, and add to
meet Destiny Pharma plc via:

 

https://www.investormeetcompany.com/destiny-pharma-plc/register-investor
(https://www.investormeetcompany.com/destiny-pharma-plc/register-investor)

Investors who already follow Destiny Pharma plc on the Investor Meet Company
platform will automatically be invited.

 For further information please contact:

 

Destiny Pharma plc
Neil Clark, CEO

Shaun Claydon, CFO

+44 (0)1273 704 440
pressoffice@destinypharma.com
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

 

Optimum Strategic Communications  (https://www.optimumcomms.com/)

Mary Clark / Manel Mateus / Eleanor Cooper

+44 (0) 203 922 0891
DestinyPharma@optimumcomms.com
(https://www.destinypharma.com/2022/05/26/26-may-2022-destiny-pharma-plc-board-changes/blank)

 

finnCap Ltd (Nominated Advisor and Broker)
Geoff Nash / Abigail Kelly / George Dollemore, Corporate Finance

Alice Lane / Nigel Birks / Harriet Ward, ECM

+44 (0) 207 220 0500

 

MC Services AG
Anne Hennecke / Andreas Burckhardt

+49-211-529252-12

 

About Destiny Pharma

Destiny Pharma is a clinical stage, innovative biotechnology company focused
on the development of novel medicines that can prevent life-threatening
infections. Its pipeline has novel microbiome-based biotherapeutics and XF
drug clinical assets including NTCD-M3, a Phase 3 ready treatment for the
prevention of C. difficile infection (CDI) recurrence which is the leading
cause of hospital acquired infection in the US and also XF-73 nasal gel, which
has recently completed a positive Phase 2b clinical trial targeting the
prevention of post-surgical staphylococcal hospital infections including MRSA.
It is also co-developing SPOR-COV(TM), a novel, biotherapeutic product for the
prevention of COVID-19 and other viral respiratory infections and has earlier
grant funded XF drug research projects.

For further information on the company, please visit www.destinypharma.com
(https://www.destinypharma.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORSFAFDUEESEEA